Differential inhibition of wild-type endothelin-converting enzyme-1 and its mutants

被引:3
作者
Savage, P
De Lombaert, S
Shimada, K
Tanzawa, K
Jeng, AY
机构
[1] Novartis Pharmaceut Corp, Metab & Cardiovasc Dis Res, Summit, NJ 07901 USA
[2] Sankyo Co Ltd, Biol Res Labs, Tokyo 140, Japan
关键词
endothelin-converting enzyme; mutants; phosphoramidon; CGS; 26303; 31447; zinc-metalloprotease inhibitor;
D O I
10.1097/00005344-199800001-00007
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
The purpose of this study was to determine the effect of mutation of rat endothelin-converting enzyme-1 (ECE-1) on the potencies of various inhibitors. The two amino acids mutated were Cys(412). which was shown to link the two monomeric enzymes to form a dimer, and Glu(752), postulated to be involved in substrate and inhibitor binding. No significant effects were noted when Glu(752) was replaced by an acidic (E752D) or uncharged (E752Q) residue. Replacing Glu(752) by a basic residue (E752R) slightly weakened the potencies of the inhibitors. In contrast, a significant decrease in the potencies was observed with the monomeric enzyme C412S. Phosphoramidon inhibited the wild-type ECE-1 with an IC50 of 1.5 muM, but it was about sixfold weaker for the C412S mutant. CGS 31447, an aminophosphonic acid, inhibited the wild-type and C412S enzymes with IC50 values of 5.8 and 76 nM, respectively. A similar degree of change in the potencies was also seen with CGS 25015, a thiol-containing compound, which inhibited the respective enzymes with IC50 values of 17 and 190 muM. These results suggest that the charge in Glu(752) may not be important for inhibitor binding and that the dimeric ECE-1 is more susceptible to inhibition than the monomeric enzyme.
引用
收藏
页码:S16 / S18
页数:3
相关论文
共 6 条
[1]
Potent non-peptidic dual inhibitors of endothelin-converting enzyme and neutral endopeptidase 24.11 [J].
DeLombaert, S ;
Stamford, LB ;
Blanchard, L ;
Tan, J ;
Hoyer, D ;
Diefenbacher, CG ;
Wei, DC ;
Wallace, EM ;
Moskal, MA ;
Savage, P ;
Jeng, AY .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (08) :1059-1064
[2]
RUBANYI GM, 1994, PHARMACOL REV, V46, P325
[3]
QUANTITATION OF PLASMA ENDOTHELINS [J].
SAVAGE, P ;
JENG, AY .
ANALYTICAL BIOCHEMISTRY, 1993, 213 (02) :434-436
[4]
Rat endothelin-converting enzyme-1 forms a dimer through Cys(412) with a similar catalytic mechanism and a distinct substrate binding mechanism compared with neutral endopeptidase-24.11 [J].
Shimada, K ;
Takahashi, M ;
Turner, AJ ;
Tanzawa, K .
BIOCHEMICAL JOURNAL, 1996, 315 :863-867
[5]
TRAPANI AJ, 1993, BIOCHEM MOL BIOL INT, V31, P861
[6]
Molecular pharmacology of endothelin converting enzymes [J].
Turner, AJ ;
Murphy, LJ .
BIOCHEMICAL PHARMACOLOGY, 1996, 51 (02) :91-102